Article

Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders

and National Center for Neurology, Neurosurgery and Psychiatry (Y.I.), Tokyo, Japan.
Neurology (Impact Factor: 8.3). 05/2013; 80(24). DOI: 10.1212/WNL.0b013e318296ea08
Source: PubMed

ABSTRACT OBJECTIVES: To analyze aquaporin-4 (AQP4) antibody-positive patients who do not fulfill the current diagnostic criteria of neuromyelitis optica (NMO) and NMO spectrum disorders (NMOSD). METHODS: We used a cell-based assay (CBA) with AQP4-transfected cells to detect AQP4 antibody in 298 consecutive patients with inflammatory CNS disorders seen at Tohoku University Hospital from 2007 to 2012. The patients were diagnosed as NMO, NMOSD, multiple sclerosis, or others using the respective current diagnostic criteria. The seropositive samples by CBA were also tested using a commercial ELISA. RESULTS: Seventy-two patients were AQP4 antibody positive. Among them, 18.1% (13/72) did not meet the NMO or NMOSD criteria (7 with monophasic optic neuritis, 2 with attacks restricted to the brainstem, and 4 with myelitis with less than 3 vertebral segments) and 84.6% (11/13) of these had only a single attack. The ELISA results were negative in 38.4% (5/13) of those patients, and they had lower antibody titers by CBA than patients with NMO/NMOSD. Although these patients had a shorter follow-up and few attacks, they shared some clinical features with NMO/NMOSD patients such as onset age, female predominance, presence of other autoantibodies, severe optic neuritis attacks, centrally located spinal cord lesions, persisting hiccups, and nausea or vomiting episodes. CONCLUSIONS: AQP4 antibody-positive patients with single or recurrent attacks of optic neuritis, myelitis, or brain/brainstem disease not fulfilling the current criteria of NMO or NMOSD may not be uncommon, and they should also be included in the NMO spectrum.

Download full-text

Full-text

Available from: Tatsuro Misu, Aug 27, 2015

Click to see the full-text of:

Article: Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders

360.65 KB

See full-text
0 Followers
 · 
274 Views
    • "Additionally , we did no retrieve enough studies to conduct a subgroup analysis for the different peptides used with the CBA (Mader et al., 2010; Pisani et al., 2013; Marignier et al., 2013) technique or the different tissues employed in the TBA (Fazio et al., 2009; Long et al., 2012a). Finally, we should emphasize that the studies included in our meta-analysis were those with patients diagnosed with definitive NMO; studies of patients with neuromyelitis optica spectrum disorder were intentionally excluded (Kang et al., 2012; Sato et al., 2013; S.-H. Kim et al., 2012 , , Kim et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibodies against water channel protein aquaporin 4 (AQP4) in astrocytes play a role in the etiology and physiopathology of neuromyelitis optica (NMO); detection of this immunoglobulin in serum is highly suggestive of this diagnosis. There are several immunoassays to detect the antibody with different sensitivities and specificities. We conducted a meta-analysis to determine the overall diagnostic accuracy from these tests. We conducted a systematic review in five different electronic databases: Pubmed, Embase, The Cochrane Library, Scopus, Database of Abstracts of Reviews of Effect (DARE) and Lilacs. We included both case control and consecutive enrollment studies that evaluated the performance of the immunoassays in patients with suspected NMO in comparison with the 2006 Wingerchuk diagnostic criteria. Articles were assessed by two different reviewers, who also extracted data. 30 studies for three different immunoassays were included in the meta-analysis. To obtain a summary estimate for the sensitivity and specificity with 95% confidence interval a bivariate random effect model was used. The approximated sensitivity for the cell based assay (CBA), the tissue-based assay (TBA) and the ELISA test were 0.76(95% CI 0.67-0.82), 0.59(95% CI 0.50-0.67), and 0.65(95% CI 0.53-0.75) respectively. The mean specificity of the CBA was 0.99 (95% CI 0.97-0.99), TBA 0.98 (95% CI 0.97-0.99) and ELISA 0.97(95% CI 0.96-0.99). AQP4 detection in serum with immunoassay is a great tool for the diagnosis of patients with NMO, due to the high specificity, allowing the clinician to differentiate this disease from other neurological conditions that resemble NMO. Copyright © 2015 Elsevier B.V. All rights reserved.
    06/2015; 4(4). DOI:10.1016/j.msard.2015.06.003
  • Journal of neuro-ophthalmology: the official journal of the North American Neuro-Ophthalmology Society 09/2013; 33(3):209-12. DOI:10.1097/WNO.0b013e3182a1e6aa · 1.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Two patients with longitudinally extensive myelopathy were initially biopsied for suspected spinal cord tumors. Both patients were later diagnosed with neuromyelitis optica spectrum disorders (NMOSD) supported by their AQP4-seropositivity. Pathological review of both biopsies revealed demyelinated lesions with thickened vessel walls and tissue rarefaction. Immunohistochemical staining demonstrated findings compatible with acute NMOSD lesions in one case while the other case exhibited findings consistent with chronic NMOSD lesions. A pre-biopsy differential diagnosis of longitudinally extensive spinal cord tumors should include NMOSD. Specific biopsy features, such as cystic changes with vascular wall thickening and astrocyte injury, should raise suspicion for NMOSD.
    Multiple Sclerosis 09/2013; 20(5). DOI:10.1177/1352458513505350 · 4.86 Impact Factor
Show more